forty-four previously untreated patients with advanced non-small-cell lung cancer were treated in a randomized trial comparing platinum ( 60 mg/m2 ) , doxorubicin ( 40 mg/m2 ) , and vp-16 ( 150 mg/m2 ) ( pav ) with platinum ( 60 mg/m2 ) , 4'-epidoxorubicin ( 50 mg/m2 ) , and vp-16 ( 150 mg/m2 ) ( pev ) .
C0013089
doxorubicin
C0058890
pav